Such doctors face a “dilemma,” Dr. Carlawish said, “the moment when there is no decision to resolve all uncertainties and resolve ethical concerns.”
“It puts us in a bad place,” agreed Dr. Curry Navishop, a geriatrician at the University of Nebraska Medical Center. Ethically, she added, “If this drug is available now, I would feel I couldn’t prescribe it.”
Even when individual physicians are working on patient advice, hospitals and healthcare systems are devising protocols to make Aduhelm more widely available, perhaps within a few weeks.
At the Mayo Clinic, Dr. Ronald Petersen, a neurologist who oversees the Alzheimer’s Disease Research Center, said, “It’s pretty close to the inclusion and exclusion criteria used in the study.”
That is, only patients with mild cognitive impairment or early-stage Alzheimer’s disease are eligible after MRI to rule out certain conditions and risks, and PET scans or lumbar puncture to confirm the presence of amyloid. Means The mayonnaise protocol excludes people taking anticoagulants such as warfarin and erikis, as in clinical trials.
“Rather than you come in and say’I’m a little forgetful’, I say’this is this medicine’,” said Dr. Petersen. However, he admitted that not all providers employ such safeguards.
Dr. Eric Widera, a geriatrician at the University of California, San Francisco, expressed similar concerns. This is the first medicine ever performed. “
New Alzheimer’s Disease Drugs Offer More Questions Than Answers
Source link New Alzheimer’s Disease Drugs Offer More Questions Than Answers